Vincristine pharmacokinetics in children with Down syndrome

Pediatric Blood and Cancer

Volumn 52, Issue 1, 2009, Pages 123-125

  Lönnerholm, Gudmar ^a   Frost, Britt Marie ^a   Söderhäll, Stefan ^b   De Graaf, Siebold S N ^c  

^a UNIVERSITY CHILDREN S HOSPITAL   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

ALL; Down syndrome; Pharmacokinetics; Vincristine

Indexed keywords

ASPARAGINASE; CYTARABINE; ETOPOSIDE; PREDNISOLONE; VINCRISTINE;

ACUTE LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ARTICLE; BLOOD SAMPLING; BOLUS INJECTION; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DOWN SYNDROME; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG SAFETY; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; LEUKEMOGENESIS; LEUKOCYTE COUNT; MALE; NEUROTOXICITY; PANCYTOPENIA; PHENOTYPE; PLASMA CONCENTRATION-TIME CURVE; PRESCHOOL CHILD; PRIORITY JOURNAL; PROGNOSIS; SCHOOL CHILD; T LYMPHOCYTE; CASE CONTROL STUDY; INFANT; PHARMACOKINETICS;

ADOLESCENT; CASE-CONTROL STUDIES; CHILD; CHILD, PRESCHOOL; DOWN SYNDROME; FEMALE; HUMANS; INFANT; MALE; PHARMACOKINETICS; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; VINCRISTINE;

EID: 58149383561     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.21691     Document Type: Article

References (15)

1. Dordelmann M, Schrappe M, Reiter A, et al. Down's syndrome in childhood acute lymphoblastic leukemia: Clinical characteristics and treatment outcome in four consecutive BFM trials. Berlin-Frankfurt-Munster Group. Leukemia 1998;12:645-651.
2. Chessells JM, Harrison G, Richards SM, et al. Down's syndrome and acute lymphoblastic leukaemia: Clinical features and response to treatment. Arch Dis Child 2001;85:321-325.
3. Zeller B, Gustafsson G, Forestier E, et al. Acute leukaemia in children with Down syndrome: A population-based Nordic study. Br J Haematol 2005;128:797-804.
4. Pui CH, Raimondi SC, Borowitz MJ, et al. Immunophenotypes and karyotypes of leukemic cells in children with Down syndrome and acute lymphoblastic leukemia. J Clin Oncol 1993;11:1361-1367.
5. Whitlock JA. Down syndrome and acute lymphoblastic leukaemia. Br J Haematol 2006;135:595-602.
6. Garre ML, Relling MV, Kalwinsky D, et al. Pharmacokinetics and toxicity of methotrexate in children with Down syndrome and acute lymphocytic leukemia. J Pediatr 1987;111:606-612.
7. Frost BM, Lonnerholm G, Koopmans P, et al. Vincristine in childhood leukaemia: No pharmacokinetic rationale for dose reduction in adolescents. Acta Paediatr 2003;92:551-557.
8. Gustafsson G, Schmiegelow K, Forestier E, et al. Improving outcome through two decades in childhood ALL in the Nordic countries: The impact of high-dose methotrexate in the reduction of CNS irradiation. Nordic Society of Pediatric Haematology and Oncology (NOPHO). Leukemia 2000;14:2267-2275.
9. Koopmans P, Gidding CE, de Graaf SS, et al. An automated method for the bioanalysis of vincristine suitable for therapeutic drug monitoring and pharmacokinetic studies in young children. Ther Drug Monit 2001;23:406-409.
10. D'Argenio DZ. Optimal sampling times for pharmacokinetic experiments. J Pharmacokinet Biopharm 1981;9:739-756.
11. de Graaf SS, Bloemhof H, Vendrig DE, et al. Vincristine disposition in children with acute lymphoblastic leukemia. Med Pediatr Oncol 1995;24:235-240.
12. Legha SS. Vincristine neurotoxicity. Pathophysiology and management. Med Toxicol 1986;1:421-427.
13. Gidding CE, Kellie SJ, Kamps WA, et al. Vincristine revisited. Crit Rev Oncol Hematol 1999;29:267-287.
14. Frost BM, Gustafsson G, Larsson R, et al. Cellular cytotoxic drug sensitivity in children with acute leukemia and Down's syndrome: An explanation to differences in clinical outcome? Leukemia 2000;14:943-944.
15. Zwaan CM, Kaspers GJ, Pieters R, et al. Different drug sensitivity profiles of acute myeloid and lymphoblastic leukemia and normal peripheral blood mononuclear cells in children with and without Down syndrome. Blood 2002;99:245-251.